Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
复制标题
DOI：
10.1016/j.eclinm.2021.101226
复制
发表时间：
2022-01
影响因子：
15.1
通讯作者：
Wan Y
中科院分区：
文献类型：
--
作者：
Feng Y;Zhang Y;He Z;Huang H;Tian X;Wang G;Chen D;Ren Y;Jia L;Wang W;Wu J;Shao L;Zhang W;Tang H;Wan Y
灭活COVID-19疫苗在免疫力完整的普通人群中安全有效。然而，它们的安全性和免疫原性尚未在艾滋病毒感染者（PLWH）中得到证实。在中国湖北省疾病预防控制中心，42名接受联合抗逆转录病毒治疗（cART）稳定的HIV-1感染者和28名健康个体入组了这项开放标签双臂非随机研究。分别于2021年4月22日和2021年5月25日接种了两剂灭活COVID-19疫苗（BBIBP-CorV）。通过观察临床不良事件和征集的局部和全身反应来评价疫苗的反应原性。通过抗加标IgG ELISA和替代中和试验测量体液应答。通过流式细胞术测量细胞介导的免疫应答和疫苗诱导的T细胞活化。所有HIV-1感染者在基线（659·0 ± 221·9 cells/μL）和接种后4周（476·9 ± 150·8 cells/μ L）时的CD 4 + T细胞计数均>200 cells/μ L。在所有参与者中未观察到征集性不良反应。在PLWH和健康个体中引起类似的结合抗体、中和抗体和S蛋白特异性T细胞应答。基线CD 4 +/CD 8 + T细胞比率低（<0.6）的PLWH在接种后产生的抗体应答低于基线CD 4 +/CD 8 + T细胞比率中等（0.6 ± 1.0）或高（≥ 1.0）的PLWH（P<0.01）。免疫后PLWH患者的CD 3+、CD 4+、CD 8 + T细胞计数均显著下降（P<0.0001），但未导致任何不良临床表现。此外，我们还发现PLWH队列中的总体HIV-1病毒载量在接种疫苗后显著下降（P= 0.0192）。HIV-1病毒载量的改变与疫苗诱导的CD 4 + T细胞活化无明显相关性（P> 0.2）。我们的数据表明，灭活SARS-CoV-2疫苗在PLWH中是安全的，免疫原性的，这些PLWH在cART中稳定，病毒载量抑制，CD 4 + T细胞计数> 200个细胞/μL。然而，疫苗诱导的免疫在PLWH中的持续性需要进一步研究。
Inactivated COVID-19 vaccines are safe and effective in the general population with intact immunity. However, their safety and immunogenicity have not been demonstrated in people living with HIV (PLWH). 42 HIV-1 infected individuals who were stable on combination antiretroviral therapy (cART) and 28 healthy individuals were enrolled in this open-label two-arm non-randomized study at Hubei Provincial Center for Disease Control and Prevention, China. Two doses of an inactivated COVID-19 vaccine (BBIBP-CorV) were given on April 22, 2021 and May 25, 2021, respectively. The reactogenicity of the vaccine were evaluated by observing clinical adverse events and solicited local and systemic reactions. Humoral responses were measured by anti-spike IgG ELISA and surrogate neutralization assays. Cell-mediated immune responses and vaccine induced T cell activation were measured by flow cytometry. All the HIV-1 infected participants had a CD4+ T cell count >200 cells/μL both at baseline (659·0 ± 221·9 cells/μL) and 4 weeks after vaccination (476·9 ± 150·8 cells/μL). No solicited adverse reaction was observed among all participants. Similar binding antibody, neutralizing antibody and S protein specific T cell responses were elicited in PLWH and healthy individuals. PLWH with low baseline CD4+/CD8+ T cell ratios (<0·6) generated lower antibody responses after vaccination than PLWH with medium (0·6∼1·0) or high (≥1·0) baseline CD4+/CD8+ T cell ratios (P<0·01). The CD3+, CD4+ and CD8+ T cell counts of PLWH decreased significantly after vaccination (P<0·0001), but it did not lead to any adverse clinical manifestation. Moreover, we found that the general HIV-1 viral load among the PLWH cohort decreased significantly after vaccination (P=0·0192). The alteration of HIV-1 viral load was not significantly associated with the vaccine induced CD4+ T cell activation (P>0·2). Our data demonstrated that the inactivated SARS-CoV-2 vaccine was safe, immunogenic in PLWH who are stable on cART with suppressed viral load and CD4+ T cell count > 200 cells/μL. However, the persistence of the vaccine-induced immunities in PLWH need to be further investigated.
登录
查看更多内容
DOI：
10.3390/diagnostics11101757
发表时间：
2021-09-24
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Chan KH;Leung KY;Zhang RR;Liu D;Fan Y;Chen H;Yuen KY;Hung IF
通讯作者：
Hung IF
影响因子：
3.8
作者：
Avelino-Silva, Vivian I.;Miyaji, Karina T.;Kallas, Esper G.
通讯作者：
Kallas, Esper G.
影响因子：
5.8
作者：
Strindhall, Jan;Ernerudh, Jan;Bengner, Malin
通讯作者：
Bengner, Malin
DOI：
10.1016/s2352-3018(21)00103-x
发表时间：
2021-08
期刊：
The lancet. HIV
影响因子：
--
作者：
Frater J;Ewer KJ;Ogbe A;Pace M;Adele S;Adland E;Alagaratnam J;Aley PK;Ali M;Ansari MA;Bara A;Bittaye M;Broadhead S;Brown A;Brown H;Cappuccini F;Cooney E;Dejnirattisai W;Dold C;Fairhead C;Fok H;Folegatti PM;Fowler J;Gibbs C;Goodman AL;Jenkin D;Jones M;Makinson R;Marchevsky NG;Mujadidi YF;Nguyen H;Parolini L;Petersen C;Plested E;Pollock KM;Ramasamy MN;Rhead S;Robinson H;Robinson N;Rongkard P;Ryan F;Serrano S;Tipoe T;Voysey M;Waters A;Zacharopoulou P;Barnes E;Dunachie S;Goulder P;Klenerman P;Screaton GR;Winston A;Hill AVS;Gilbert SC;Pollard AJ;Fidler S;Fox J;Lambe T;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
影响因子：
3.8
作者：
Tebas, Pablo;Frank, Ian;Sullivan, Kathleen
通讯作者：
Sullivan, Kathleen